A single blinded randomized controlled trial assessing the effect of photobiomodulation therapy on neuron specific biomarkers in type II diabetes mellitus patients with peripheral neuropathy
Authors' conclusion
Serum levels of NSE and CGRP may be good indicators of effectiveness of photobiomodulation in reducing neuropathic pain and other symptoms in individuals with DPN. Reduced neuropathic symptoms, improved protective sensation of foot and quality of life, and reduced neuropathic pain was observed in intervention group.
Study context
- Population
- T2D patients with peripheral neuropathy
- Participants
- 200 patients
- Comparison
- Photobiomodulation therapy vs sham laser
- Interventionn = 100
- Controln = 100reference
Methodological detailssingle blinded, sham-controlled
- Single blinded
- Sham-controlled
Primary result
As reported in the abstract
Neuron-specific biomarkers and clinical neuropathy measures in intervention group · four weeks after treatment
- Significant change in serum Neuron specific enolase (NSE)
- p < 0.001
- Significant change in Calcitonin gene related peptide (CGRP)
- p < 0.001
- Significant change in MNSI
- p < 0.001
- Significant change in VPT
- p < 0.001
- Significant change in Numeric Pain Rating Scale (NPRS)
- p < 0.001
- Significant change in NQL
- p < 0.001
- No change in Nerve Growth Factor (NGF) levels
- p = 0.937
Original publication
A single blinded randomized controlled trial assessing the effect of photobiomodulation therapy on neuron specific biomarkers in type II diabetes mellitus patients with peripheral neuropathy. Diabetes Res Clin Pract. Published 14 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →